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Abstract
Background Squamocellular anal carcinoma is increasingly
diagnosed in patients with risk factors.
Methods State-of-the-art imaging with magnetic resonance
imaging (MRI) using phased-array coils and volumetric
multidetector computed tomography (CT) provides detailed
visualisation of anal disorders, identification and extent
assessment of neoplastic tissue, detection and characterisa-
tion of nodal and visceral metastases. MRI has been recom-
mended by the European Society for Medical Oncology
(ESMO) as the preferred modality of choice to stage anal
cancer, taking into account the maximum tumour diameter,
invasion of adjacent structures and regional lymph node
involvement.
Results Cross-sectional imaging techniques allow the iden-
tification of coexisting complications, and differentiation
from other perineal abnormalities.
Conclusion Cross-sectional imaging is useful for planning
radiotherapy, surgical drainage or salvage abdomino-
perineal resection. After chemo-radiotherapy, MRI follow-
up provides confident reassessment of therapeutic response,
persistent or recurrent disease.
Teaching Points
• Anal carcinoma is increasingly diagnosed in patients with
human immunodeficiency virus (HIV), anoreceptive inter-
course, chronic inflammatory bowel disease.
• An established association exists with human papilloma-
virus (HPV) infection and premalignant intra-epithelial
dysplasia.
• Phased-array MRI is recommended as the preferred im-
aging modality for regional staging.
• Imaging allows detection of infectious complications,
planning of radiotherapy or salvage surgery.
• Follow-up MRI allows reliable assessment of therapeutic
response after chemo-radiotherapy.
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Introduction
An uncommon malignancy in the general population, squa-
mocellular anal carcinoma (SCAC) accounts for approxi-
mately 1 % of all gastrointestinal neoplasms and less than
5 % of anorectal tumours. In past decades, SCAC was
usually diagnosed at a relatively advanced age with a
significant female predominance, and believed to be an
indolent disease secondary to chronic irritation. In recent
years, similarly to uterine cervix dysplastic changes, onco-
genic human papillomavirus (HPV) has been detected in
the vast majority (up to 90 %) of invasive SCACs, and
linked to the development of low- and high-grade prema-
lignant anal intra-epithelial neoplasms (AIN), particular-
ly with high-risk or multiple HPV serotypes infection
[1, 2].
Furthermore, the incidence of SCAC is steadily increas-
ing, particularly in patients with risk factors such as human
immunodeficiency virus (HIV) infection, history of anore-
ceptive intercourse, coexistent cervical dysplasia or cancer,
immunosuppression, inflammatory bowel diseases (IBD)
and cigarette smoking. Currently, at least half of SCACs
occur in relatively young (40–60 years) HIV-positive indi-
viduals, most often men who have sex with men (MSM)
[3–5].
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Regional anatomy and imaging techniques
The surgical anus is about 4 cm long from the anorectal
junction to the perianal skin on the external anal margin
(verge). The internal anal sphincter consisting of smooth
muscle is separated from the external, striated muscle
sphincter by the fatty intersphincteric space. Along with
the puborectalis and levator ani muscles, the external anal
sphincter forms the sphincter complex. Located approxi-
mately halfway along the anus, the dentate line marks the
transition from the squamous epithelium to the intestinal
mucosa. Thus, histologically SCACs can be either keratinis-
ing or non-keratinising according to their origin below or
above the dentate line, although with similar biological
behaviour [6, 7].
Lymphatic drainage of anal neoplasms varies according
to the primary lesion site. Anal margin and anal canal SCAC
originating distal to the dentate line drain to the inguinal and
femoral lymph nodes. When the primary tumour arises
above the dentate line, regional lymph nodes include the
inguinal, internal iliac and perirectal nodes, whereas the
external, common iliac and para-aortic nodes are considered
non-regional [6–8].
Because of its anatomical location, in most cases SCAC
is diagnosed clinically in patients with rectal bleeding, pain,
discharge or palpable masses. Alternatively, lesions may be
detected during follow-up of high-risk individuals. Follow-
ing physical examination including digital rectal and vaginal
examination, ano-proctoscopy and biopsy, imaging is re-
quired to evaluate the local extent of the lesion, lymph node
involvement, possible invasion of adjacent organs and dis-
tant metastases [6, 9].
Imaging the anal canal and perianal structures may prove
technically challenging to perform and interpret. In past
years, trans-anal ultrasound (TRUS) and magnetic reso-
nance imaging (MRI) techniques allowed an accurate
Fig. 2 A 62-year-old female with biopsy-proven SCAC. Axial T2-
weighted (a), post-contrast fat-suppressed axial (b) and coronal (c) T1-
weighted images, and corresponding enhanced image from body CT
(d) show a 5.5-cm long (T3) enhancing tumour with infiltration of the
left ischioanal fatty space (arrowheads)
Fig. 3 A 57-year-old woman undergoing abdomino-pelvic MDCT for
unrelated reasons. Post-contrast axial (a) and coronal reformatted (b)
detailed images of the anorectal region identify an unexpected 2-cm
right-sided enhancing anal nodule. Subsequent clinical and bioptic
assessment confirmed poorly symptomatic ulcerated SCAC
Fig. 1 A 40-year-old MSM with bioptic diagnosis of SCAC. Axial (a)
and sagittal (b) T2-weighted images show 2-cm hyperintense nodule
contained within the internal sphincter muscle, intensely enhancing as
seen on post-contrast fat-suppressed coronal T1-weighted image (c),
consistent with T1 tumour (arrowheads)
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assessment of tumour size and depth of mural invasion [7,
10, 11]. Unfortunately, in patients with anal lesions, posi-
tioning of endoanal sonography probes and MRI coils is
hampered by pain and stricture. Trans-anal imaging com-
bines an excellent spatial detail with a limited field-of-view
that prevents panoramic assessment of entire ischiorectal
spaces and of regional lymph nodes. Furthermore, TRUS
has limited specificity for differentiation of residual tumour
versus post-treatment fibrosis [11–13].
Currently, MRI performed using external phased-array
coils on high-magnetic-field scanners is the imaging modal-
ity of choice to investigate the anal region. Significant
advantages of MRI include its native multiplanar capability,
superior soft-tissue differentiation, biological non-
invasiveness and optimal safety profile of gadolinium-
based contrast agents. No special patient preparation is
needed. Acquisition protocols heavily rely on high-
resolution T2-weighted sequences along three planes, with
coronal and axial scans planned slightly oblique, respective-
ly parallel and perpendicular to the long axis of the anal
canal. Despite the increased tumour conspicuity provided by
background fat suppression, short-tau inversion recovery
(STIR) sequences are less useful because of limited spatial
detail and difficulty to delineate anatomic landmarks. At our
Centre, T1-weighted sequences including fat suppression in
at least one plane are routinely acquired following standard-
dose intravenous gadolinium contrast, to allow detection of
lesion enhancement. Conversely, other authors discourage
post-contrast MRI acquisitions by stating that enhanced
images do not offer additional information to the high soft
Fig. 4 An elderly, 92-year-old man with previous prostatectomy and
kidney failure has unenhanced MRI. Sagittal T2- (a) and axial T1-
weighted (b) images show 5-cm long solid, inhomogeneous neoplastic
tissue (*) extending from the anus to encase the proximal urethra (note
catheter in place)
Table 1 Tumour-node-metasta-
sis (TNM) staging of anal carci-
noma according to lesion site of
origin
Anal canal Anal margin
Primary tumour (T)
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Tumour ≤2 cm in greatest dimension
T2 Tumour 2–5 cm in greatest dimension
T3 Tumour >5 cm in greatest dimension
T4 Tumour of any size invading adjacent organ(s) e.g.
vagina, urethra, bladder
Tumour invading deeper structures
(skeletal muscle, cartilage)
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in perirectal lymph node(s) Regional lymph node metastasis
N2 Metastasis in unilateral internal iliac and/or inguinal lymph node(s)
N3 Metastasis in internal iliac and perirectal lymph nodes and/or bilateral internal iliac and/or
bilateral inguinal lymph nodes
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Fig. 5 A 32-year-old HIV-positive woman with clinical diagnosis of
anovaginal fistula. Axial T2-weighted (a) and post-contrast fat-
suppressed axial T1-weighted (b) images show inhomogeneous anal
tissue invading the left aspect of the vagina (arrowheads), with internal
non-enhancing necrosis and peripheral enhancement. Biopsy diag-
nosed SCAC with superimposed infection
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tissue contrast intrinsic to T2-weighted imaging [7, 10,
13–15].
Although with limited contrast resolution compared with
MRI, volumetric multidetector computed tomography
(MDCT) acquisitions including image reformations along
arbitrary planes allow visualisation of anorectal abnormali-
ties in their cranio-caudal extent with relationship to key
anatomical landmarks such as the sphincter complex
[16–18].
Imaging features and tumour staging
MRI provides a detailed visualisation of the anal canal and
nearby anatomical structures. Although the dentate line is
not directly recognisable, its position can be inferred as it
corresponds approximately to the upper portion of external
sphincter muscles. Sensitivity of TRUS and MRI for the
identification of SCAC has been reported to approach 90–
100 %, with high concordance regarding tumour size, al-
though on a limited number of patients, and more precise
results with ultrasound for smaller, superficial tumours [19].
Neoplastic tissue in the anal canal has low-to-
intermediate T1 signal intensity and positive enhancement
after intravenous gadolinium contrast. On T2-weighted and
STIR sequences, untreated neoplasms display intermediate
signal intensity, lower to that of normal ischioanal fat and
almost always superior to the internal reference standard
represented by uninvolved anal sphincters and gluteal
muscles (Figs. 1, 2). Although with limited sensitivity com-
pared with MRI, on CT images SCAC may be detected as
solid, enhancing nodules or masses within the anus (Figs. 2,
3). Progressive heterogeneity is observed in larger lesions
(Fig. 4) [7, 9, 10, 13].
Staging is essential for both prognostic information and
correct therapeutic planning, and is performed according to
the UICC/AJCC tumour-node-metastasis (TNM) system
(Table 1), including local lesion extent, lymph node status
and distant metastatic spread. In 2010 the European Society
for Medical Oncology (ESMO) recommended MRI as the
primary imaging modality to accurately stage SCAC, taking
into account the maximum tumour diameter, possible inva-
sion of adjacent organs and nodal involvement [6, 13].
Particular care should be applied to choosing the longest
lesion diameter on T2-weighted images, since correct T
parameter staging relies on this measure being below
2 cm, over 5 cm or intermediate (Fig. 1) [7, 9, 10, 13].
MRI demonstrates good correlation with physical find-
ings concerning T stage, whereas infiltration of adjacent
organs and sometimes tumour size are clinically underesti-
mated. Extramural neoplastic spread may involve the
sphincter complex muscles (external sphincter, levator ani
and puborectalis) and most commonly occurs towards the
anterior urogenital triangle with possible vaginal, urethral or
bladder involvement. Sometimes, the tumour may also ex-
tend laterally with invasion of the ischioanal fossa (Fig. 2),
superiorly to the rectum and mesorectal compartment, or
Fig. 6 A 65-year-old woman with history of previously treated small
SCAC 3 years earlier. Axial T2- (a) and post-contrast T1-weighted (b)
images show roundish 1-cm left inguinal node (arrowheads) with
internal fluid-like necrosis and inhomogeneous enhancement, con-
firmed by ultrasound (c) as hypoechoic with loss of normal nodal
structure. Surgical exeresis (postoperative status as seen in d, follow-
up MRI) confirmed metastatic node from SCAC
Fig. 7 The same patient as in
Fig. 2. Axial T2-weighted (a,b)
and post-contrast fat-suppressed
T1-weighted (c) images show
inguinal nodal metastases,
larger on left side (arrowheads)
plus bilateral enhancing
perirectal adenopathies (arrows)
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inferiorly to the skin and subcutaneous planes of the peria-
nal region. In such instances, T2-hyperintense solid tissue is
seen infiltrating the even more hyperintense fat in the
ischiorectal (Fig. 2) and subcutaneous spaces, encasing the
lower signal intensity skeletal muscles, or isointense struc-
tures such as the vagina (Fig. 5), prostate and urethra
(Fig. 4). Notably, radiologists should remember that anal
canal carcinoma directly invading the rectal wall, perianal
skin, subcutaneous or the sphincter muscle does not imply
assessing the tumour stage as T4. For anal margin SCAC, a
T4 lesion is defined by invasion of deeper structures such as
the skeletal muscle or cartilage [9, 10, 13].
The incidence of regional nodal involvement increases
with primary tumour size. Lymph node metastases may be
present (in 25 % of cases) even with superficial (up to T2)
SCACs, and are unreliably assessed clinically. Nodal stag-
ing evaluation relies on the distance from the primary tu-
mour rather than on the number of involved nodes [6]. MRI
is highly helpful to assess lymph node metastatic involve-
ment, although the mere size criterion is far from accurate
and associated with both false-positive and false-negative
results. Short-axis threshold values of 8 mm, 5 mm and
10 mm have been suggested for pelvic, perirectal and ingui-
nal lymph nodes, respectively. Additional helpful features to
increase specificity include loss of the normal bean-shaped
morphology and fatty hilum, internal T1 and T2 signal
heterogeneity with central necrosis, and inhomogeneous
enhancement (Figs. 6, 7) [10, 13].
As suggested by ECCO guidelines, search for distant
spread is usually performed by means of contrast-
enhanced body MDCT, with conventional imaging appear-
ances of liver and lung metastases. Dissemination is very
uncommon (less than 5 % of patients at initial diagnosis, and
is usually encountered in association with post-treatment
recurrence [20]. Alternatively, in immunocompetent patients
18F-fluorodeoxygluocose positron emission tomography
(FDG-PET/CT) has high specificity for nodal and visceral
dissemination. At diagnosis, FDG-PET/CT may alter stag-
ing of anal SCAC in 20 % of patients, leading to inclusion
of involved pelvic or inguinal lymph nodes in the radiation
field [6, 7].
Complications
In our experience, not infrequently anal tumours coexist
with inflammatory conditions such as proctitis and abscess-
es. In such instances, MDCT and MRI provide confident
Fig. 9 A 53-year-old man with purulent drainage and clinical diagno-
sis of perianal inflammation. Axial images (b,c) from urgent contrast-
enhanced MDCT show solid circumferential thickening of the anal
canal (arrowheads) associated with abscess collections with mixed
gas-fluid content (*) and fistulas crossing the ischioanal space. Surgical
examination under anaesthesia including biopsies revealed ulcerated
SCAC with superinfection. After surgical drainage and subsequent
chemo-radiotherapy, MRI (c) shows complete resolution of both in-
flammatory and neoplastic changes with residual T2-hypointense fi-
brotic tracks
Fig. 8 A 60-year-old man with AIDS and clinical finding of ulcero-
fungating anal mass. Axial (a) and coronal reformatted (b) CT images
show moderately heterogeneous tissue (*) in its entire longitudinal
extent from the anorectal junction to below the anal verge, associated
with large necrotic iliac adenopathies (* in c). Biopsy confirmed super-
infected SCAC
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detection of perirectal inflammatory changes and purulent
collections that are differentiated from solid neoplastic tissue,
thus allowing a correct therapeutic choice including surgical
drainage as necessary (Figs. 5, 8, 9, 10). Resolution of asso-
ciated inflammatory changes during treatment is easily mon-
itored by cross-sectional imaging (Figs. 9, 10) [15, 21].
Furthermore, cross-sectional imaging particularly with
MRI also proves useful to differentiate anal carcinoma from
other causes of local pain and perineal masses, such as
pilonidal sinus diseases, Gartner duct or Bartolini gland
Fig. 10 A 39-year-old HIV-infected man with biopsy-proven SCAC.
Staging MRI confirms left-sided anal thickening (arrowheads) with
abnormal T2 signal intensity (a) and strong contrast enhancement (b).
Incidentally, two abscess collections with necrotic content and periph-
eral enhancement are seen ventrally, connected to the anal canal by a
fistulous track (arrow in c). Subtotal regression of changes after treat-
ment is seen on follow-up MRI (d)
Fig. 11 An 83-year-old man with known SCAC. Initial MRI shows
moderate circumferential thickening of the anus with T2-hyperintense
signal (a) and contrast enhancement (b) (arrowheads). Complete dis-
appearance of the lesion is observed on axial T2 (c) and post-contrast
fat-suppressed T1-weighted (d) images following chemo-radiotherapy
Fig. 12 A 46-year-old female patient with biopsy-proven SCAC. MRI
staging including axial (a) and coronal (b) T2-weighted images detect
a solid, 3-cm eccentric anal mass (arrowhead) consistent with T2
tumour, associated with right inguinal adenopathies with analogous
signal features. After chemo-radiotherapy, MRI follow-up (c, d) shows
complete disappearance of both anal neoplastic solid tissue and
lymphadenopathies
Fig. 13 A 46-year-old HIV-infected man with biopsy-proven SCAC.
Initially, MDCT (a) shows left-sided thickening with involvement of
the external sphincter (arrowheads). After chemo-radiotherapy, lesion
regression is observed on MRI with appearance of T2-hypointense
fibrosis (*) and hyperintense nodule (arrow) consistent with residual
tumour
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cysts, tailgut cysts, uncommon soft-tissue neoplasms, ure-
thral cancer, lymphoma or metastases [14, 22].
Treatment
In the past, SCAC was treated with abdomino-perineal
resection and permanent colostomy. Currently, anal margin
and small canal tumours without evidence of nodal spread
may be successfully excised. In all other cases, the standard
treatment includes radiation combined with mitomycin-C plus
infusional 5-FU chemotherapy, yielding an 80 % 5-year sur-
vival rate with preservation of sphincter function. Advanced
T3/T4 tumours have worse outcomes with a 40–68 % 3-year
disease-free survival. New neoadjuvant and adjuvant drugs
are being investigated to treat advanced disease. Salvage
surgery with abdomino-perineal resection is reserved for per-
sistent or recurrent tumours [3, 6, 23–25].
After radio-chemotherapy, imaging follow-up withMRI rep-
resents a useful complement to clinical evaluation in the assess-
ment of therapeutic response. Shortly after treatment
completion, interpretation of MRI is usually challenging due
to the superimposition of inflammatory changes resulting from
radiotherapy. Performed at least 6–8 weeks after treatment
completion, MRI provides confident, reproducible assessment
of post-treatment modifications. Findings indicative of a posi-
tive response include size reduction and diminished T2 signal
intensity of the treated tumour and associated adenopathies
(Figs. 10, 11, 12). The appearance of T2-hypointense signal is
consistent with fibrosis, although it does not allow excluding
minor residual neoplastic foci for sure (Fig. 13). Size decrease
usually becomes evident more than 6 months following treat-
ment. Stability in size and signal intensity of any residual
abnormality visible at MRI in the site of the treated lesion 1
year after therapy has been reported to be strongly associated
with a favourable outcome. Locoregional and/or distant recur-
rence occurs in up to 35 % of treated patients, and is strongly
associated with advanced (T3–T4) stage and nodal involvement
at presentation [7, 20]. Persistent and locally recurrent tumours
often display an aggressive behaviour, with possible extensive
invasion of the adjacent organs and pelvic bony structures, and a
tendency for lymphatic dissemination (Figs. 14) [9, 10, 13].
HIV-associated anal carcinoma
After the introduction of highly active anti-retroviral treat-
ment (HAART), people with HIV infection or acquired
Fig. 14 An elderly, 85-year-old lady with biopsy-proven SCAC and
multiple comorbidities. Initial MRI (a,b) shows showed circumferen-
tial anal wall thickening with abnormal solid signal (arrowheads)
measuring 6 cm in length, plus a suspicious centimetric left inguinal
lymph node (arrow in a), findings consistent with T3N2 lesion. After
reduced chemo-radiotherapy, follow-up MRI (c, d) 4 months later
disclosed progression and partial necrosis of both primary tumour
(arrowhead) and inguinal adenopathy (arrow), plus appearance of an
exophytic tissue mass protruding from the external anal orifice (* in d)
Fig. 15 A 40-year-old male patient with long-standing perianal
Crohn’s disease, being treated with seton. Contrast-enhanced MDCT
images (a, b, c in cranio-caudal order) show right-sided levator ani
abscess (*), extensive perianal fistulisation occupying the ischioanal
space (arrow), and marked solid-appearing circumferential anorectal
thickening (arrowheads). Abdomino-perineal resection for SCAC was
performed
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immunodeficiency syndrome (AIDS) gained a greatly im-
proved life expectancy with better immune conditions, at the
price of an increased tendency to develop tumours. Al-
though it is considered a non-AIDS-defining malignancy,
currently SCAC ranks third (8.2 %) among neoplasms ob-
served in HIV/AIDS populations, with a substantially higher
incidence in MSMs and in long-standing infected people [4,
26].
Dysplastic intraepithelial lesions are highly prevalent in
HIV-infected people, and HIV represents a marker for coin-
fection with other sexually transmitted diseases such as
HPV. Since the risk of developing SCAC increases with
the total time elapsed with CD4+ count below 200 cells/
μl, it has been hypothesised that HIV-related immune sup-
pression acts as a cofactor to HPV in the development of
anal dysplasia and progression to overt carcinoma [1, 3, 4].
Screening procedures including high-resolution ano-
scopy and cytology smears are increasingly adopted at
HIV care centres, to allow detection of SCAC precursors
and early-stage tumours amenable to limited excision and
topical therapies. Prevention should limit the occurrence of
advanced stages at diagnosis in the future [4, 26–29].
A high prevalence (at least 30 %) of anorectal complaints
is characteristic of HIV-positive patients, particularly those
practicing anoreceptive intercourse. Differential diagnosis
encompasses a wide spectrum of abnormalities, including
non-specific anal diseases such as haemorrhoids, fissures,
fistulas and abscesses, along with venereal infections, viral
ulcers, and a non-negligible (7 %) rate of neoplasms such as
SCAC, lymphoma and Kaposi’s sarcoma. Therefore, when
performing cross-sectional imaging procedures on HIV-
infected patients, even for unrelated complaints, special
attention should be paid to the anal region, with a focus on
the possible identification of solid, enhancing tissue consis-
tent with tumour that indicates need for biopsy (Figs. 5, 8,
10, 13) [21, 30, 31].
Despite initial discouraging reports, in the HAART era
HIV-positive patients are likewise treated with standard
chemo-radiation regimens, reaching satisfactory results in
terms of local control and survival rates, although with
increased toxicity and frequent local recurrences [4, 5, 26,
27, 32].
Anal carcinoma in inflammatory bowel diseases
Some literature reports have highlighted the increased risk
of anus and lower rectum carcinomas associated with long-
standing, severe perianal fistulising Crohn’s disease (CD)
(Fig. 15). In patients with CD, SCAC reaches a 14 %
proportion among all colorectal cancers, which is ten-times
higher than the usual figure. Furthermore, CD patients
Fig. 16 A 39-year-old woman with history of ulcerative colitis and
perianal inflammation. Initial multiplanar MDCT (a, b) identified
enhancing anal thickening (arrowheads) with right-sided vaginal infil-
tration and solid tissue (*) extending to reach the internal obturator
muscle. After biopsy confirmation of SCAC and surgical debulking
with colostomy, repeat MDCT (c, d) detected enlarging neoplastic
residue (*). Shortly after chemo-radiotherapy, MRI (e) detected the
formation of a thick hypointense fibrotic band in the site of the
regressed tumour (thin arrows). MRI follow-up (e) identified appear-
ance of a contralateral enhancing tissue band interpreted as suspicious
for local recurrence (arrow). After negative clinical reassessment and
PET findings, this post-treatment finding remained stable on further
MRI studies (not shown)
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develop anorectal carcinomas at a younger age (20 years
earlier) than the general population. According to the
hypothesised pathogenesis, fistulas probably allow HPV
an easier access to the epithelial layers, and chronic
mucosal regeneration may ultimately lead to neoplastic
changes. However, anal tumours may occasionally de-
velop in patients with ulcerative colitis (UC)-related
(Fig. 16) or cryptogenetic chronic perianal inflammation
[33, 34].
Diagnosis is often unsuspected or delayed because of pre-
existent, unspecific complaints and clinical assessment is
hampered by complex inflammation with stricture and local
pain. As a result, IBD-associated anal cancers are often
advanced at presentation, may require extensive surgery
plus chemotherapy and radiotherapy, and are associated
with a severe prognosis [34]. Therefore, patients with
early-onset or long-standing perianal CD should undergo
clinical and imaging surveillance, particularly when new
or changed symptoms develop. Radiologists should be
aware of the increased risk for anorectal cancer in middle-
aged IBD patients, and clearly report any solid tissue as
suspicious for neoplasm and suggest biopsy (Figs. 15, 16)
[33–35].
Conclusion
The established association with HPV infection and prema-
lignant intra-epithelial dysplastic changes provides insight
into the pathogenesis of HIV- and IBD-related anal cancers,
and the possibility of prevention or early diagnosis through
screening of high-risk individuals [1, 2].
State-of-the-art cross-sectional imaging with high-
resolution MRI using external phased-array coils and multi-
planar MDCT allow detailed, comprehensive visualisation
of abnormalities involving the anus and perineal region.
Currently, MRI represents the modality of choice for prima-
ry regional staging of SCAC, assessment of complications,
of therapeutic response following chemo-radiotherapy, and
of possible recurrences [9, 10, 13].
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